140 related articles for article (PubMed ID: 9056001)
1. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?
Lounis N; Ji B; Truffot-Pernot C; Grosset J
Antimicrob Agents Chemother; 1997 Mar; 41(3):607-10. PubMed ID: 9056001
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
JI B; Lounis N; Truffot-Pernot C; Grosset J
Antimicrob Agents Chemother; 1995 Jun; 39(6):1341-4. PubMed ID: 7574527
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
[TBL] [Abstract][Full Text] [Related]
4. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Ji B; Truffot-Pernot C; Grosset J
Tubercle; 1991 Sep; 72(3):181-6. PubMed ID: 1663283
[TBL] [Abstract][Full Text] [Related]
7. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.
Lounis N; Truffot-Pernot C; Bentoucha A; Robert J; Ji B; Grosset J
Antimicrob Agents Chemother; 2001 Nov; 45(11):3229-30. PubMed ID: 11600387
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570
[TBL] [Abstract][Full Text] [Related]
10. Activity of levofloxacin in a murine model of tuberculosis.
Klemens SP; Sharpe CA; Rogge MC; Cynamon MH
Antimicrob Agents Chemother; 1994 Jul; 38(7):1476-9. PubMed ID: 7979275
[TBL] [Abstract][Full Text] [Related]
11. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
[TBL] [Abstract][Full Text] [Related]
12. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.
Rastogi N; Labrousse V; Goh KS
Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones and tuberculosis.
Bryskier A; Lowther J
Expert Opin Investig Drugs; 2002 Feb; 11(2):233-58. PubMed ID: 11829714
[TBL] [Abstract][Full Text] [Related]
15. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R
Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446
[TBL] [Abstract][Full Text] [Related]
16. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.
Klemens SP; DeStefano MS; Cynamon MH
Antimicrob Agents Chemother; 1993 Nov; 37(11):2344-7. PubMed ID: 8285617
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
18. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
[TBL] [Abstract][Full Text] [Related]
20. First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant
Varghese B; Al-Hajoj S
Am J Trop Med Hyg; 2017 May; 96(5):1066-1070. PubMed ID: 28500800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
